ReviewExtracellular vesicles and circulating nucleic acids2026
Engineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects.
Review in Extracellular vesicles and circulating nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postbiotics, defined as inactivated microorganisms and/or their components conferring a health benefit, represent a paradigm shift from traditional probiotics by offering superior safety, stability, and precise dosing. Bacterial extracellular vesicles (BEVs), natural nanoparticles secreted by bacteria, are key mediators of microbiota-host communication. BEVs have emerged as promising natural postbiotic agents due to their ability to transport bioactive cargo and modulate host physiology. However, the therapeutic application of natural BEVs (nBEVs) is constrained by limitations, including potential safety concerns, lack of target specificity, low yield, and compositional heterogeneity. To overcome these barriers, the concept of engineered BEVs (eBEVs) has been introduced. By employing genetic modification of parent bacteria, surface functionalization, and tailored cargo loading, eBEVs can be precisely designed. This engineering transforms nBEVs into advanced, targeted delivery platforms that significantly expand the scope and efficacy of postbiotics. This review explores the vast potential of eBEVs as next-generation precision postbiotics to treat multiple disorders. Despite the transformative potential, translating eBEVs into clinical practice faces challenges. These include scalable manufacturing processes, comprehensive
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.